Tianmu Biotech supports the construction of MabSeek platform at Tsinghua University, empowering new breakthroughs in antibody research and development

Tianmu Biology Helps Tsinghua University MabSeek PlatformconstructionEmpowering new breakthroughs in antibody research and development

On December 13, 2025, the MabSeek antibody search platform at Tsinghua University was officially launched. The platform's innovation team, industry experts, and cooperative enterprises such as Tianmu Biology, Ruifudi, and Dongfulong Technology Group attended the launch ceremony to support this important practice in the field of antibody research and development with practical actions, and work together to promote the efficiency improvement, achievement transformation, and talent cultivation of antibody research and development.

Antibodies are the core foundation of biomedical diagnosis and treatment, and "long cycle, difficult screening, and slow conversion" have always been practical pain points faced by the industry. MabSeek platformInnovative approachThe intelligent integrated system for the entire process of "sample in antibody out" precisely meets this demand - by integrating AI data analysis, automated experiments, structural function analysis and other technologies, it constructs a real-time iterative loop of "wet experiment dry computing", which not only improves research and development efficiency, but also strengthens emergency response capabilities for infectious diseases, providing cutting-edge practical carriers for physicians and scientists.

Professor Zhang Linqi, the person in charge of the platform, introduced the construction of the platform. He pointed out that the MabSeek platform will become an "intelligent accelerator" for antibody research and development, innovatively integrating artificial intelligence (AI) and automated high-throughput equipment. Through deep integration of wet experiments (laboratory experiments) and dry experiments (computer simulation calculations), a complete chain of end-to-end antibody discovery and development will be built.

Dr. Wang Liyan, General Manager of Tianmu Biotechnology, introduced that Tianmu Biotechnology relies on its own technical accumulation in microfluidic technology, cell and antibody screening, and has deep cooperation with Professor Xing Xinhui and Professor Zhang Chong's team from the Department of Chemical Engineering at Tsinghua University to provide core technology and equipment support for the MabSeek platform, helping the platform operate efficiently. The relevant equipment serves the screening and functional identification of antibody molecules, and collaborates with the platform's AI algorithms and bioinformatics analysis to effectively shorten the research and development cycle and improve the accuracy of results.

The MabSeek platform brings together interdisciplinary forces from multiple departments of Tsinghua University and has received recognition from the Ministry of Education, the Ministry of Science and Technology, and the National Health CommissionWith the support of other departments, it has dual value in scientific research and teaching. Tianmu Biotechnology will also take this cooperation as an opportunity to continue to leverage its research and innovation advantages, provide technical and equipment support for the platform, and help China's antibody development achieve faster development.

About Tianmu Biotechnology High throughput Antibody Screening Platform

Tianmu Biotechnology has launched a complete one-stop solution for high-throughput monoclonal antibody development based on the cell monoclonal screening system AIOM cell,Equipped with our own professional team of application scientists, we provide customers with full process technical support from solution design to result analysis,fromQuickly and accurately screen out cells from billions of candidate cells that can stably produce high affinity and high specificity antibodies,Committed to delivering high-throughput and efficient antibody development services,Assist in achieving breakthroughs in both scientific research and industry.